Supplemental Figure 2. from Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young
Year: 2026
Type: supplementary-materials
Abstract: A) PCR amplification of the LSM1-FGFR1 fusion and breakpoint sequence identified in an osteosarcoma patient (zcc386). B) Cell number and viability of LSM1-FGFR1 and OP2-FGFR1-expressing Ba/F3 cells following IL-3 withdrawal over ten-day time course. Total number of viable cells was determined by trypan blue exclusion. Data presented as mean ± standard error of the mean (SEM) (n=3). C) Viability analysis of LSM1-FGFR1- and FGFR1OP2-FGFR1 (OP2-FGFR1)-expressing Ba/F3 cells following 96-hour (left) and 168-hour (right) IL-3 withdrawal. Viability was determined by propidium iodide exclusion, measured by flow cytometry. FGFR1 variant cell lines were compared to MSCV controls using a one-tailed unpaired t-test (*: P < 0.05, ****: P < 0.0001). Data presented as mean ± SEM (n=3). ¬¬D) Viability analysis of LSM1-FGFR1- and OP2-FGFR1-expressing Ba/F3 cells treated with a dose titration of regorafenib, AZD4547 or imatinib. Data presented as mean ± SEM (n=6).
Authors: Ashleigh M. Fordham, Lauren M. Brown, Chelsea Mayoh, Alice Salib, Zara A. Barger, Marie Wong, Terry C.C. Lim Kam Sian, Changyuan Hu, Jinhan Xie, Kate Gunther, Peter Trebilcock, Rachael L. Terry, Paulette Barahona, Pamela Ajuyah, Alexandra Sherstyuk, Anica Avila, Roxanne Cadiz, Callum M. Perkins, Andrew J. Gifford, Jie Mao, M. Emmy M. Dolman, Andrea Zhao, Luke P. O’Regan, Daniel Gorgels, Loretta M.S. Lau, David S. Ziegler, Michelle Haber, Vanessa Tyrrell, Richard B. Lock, Mark J. Cowley, Wayne Nicholls, Roger J. Daly, Paul G. Ekert, Emmy D.G. Fleuren
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7167042985